Succes with SGLT2 inhibitor in HFrEF for all three end points - PACE-CME

Succes with SGLT inhibitor in HFrEF for all three end points

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Strong evidence for colchicine in patients with chronic coronary disease
Strong evidence for colchicine in patients with chronic coronary disease
ESC 2020
Strong evidence for colchicine in patients with chronic coronary disease
- Aernoud Fiolet, MD
- Aernoud Fiolet, MD, PhD
No difference in outcomes after 5 years with anti-ischemic metabolic agent in patients after PCI
No difference in outcomes after 5 years with anti-ischemic metabolic agent in patients after PCI
ESC 2020
No difference in outcomes after 5 years with anti-ischemic metabolic agent in patients after PCI
- Prof. Freek Verheugt, MD
BP lowering should be considered irrespective of prior CVD or baseline SBP
BP lowering should be considered irrespective of prior CVD or baseline SBP
ESC 2020
BP lowering should be considered irrespective of prior CVD or baseline SBP
- Kazem Rahimi, MD
Colchicine reduces primary outcome in chronic coronary disease
Colchicine reduces primary outcome in chronic coronary disease
ESC 2020
Colchicine reduces primary outcome in chronic coronary disease
- Mark Nidorf, MD